Theranostics represents a transformative advancement in nuclear medicine by integrating molecular imaging and targeted radionuclide therapy within the paradigm of personalized oncology. This review elucidates the historical evolution and contemporary clinical applications of theranostics, emphasizing its pivotal role in precision cancer management. The theranostic approach involves the coupling of diagnostic and therapeutic radionuclides that target identical molecular biomarkers, enabling simultaneous visualization and treatment of malignancies such as neuroendocrine tumors (NETs), prostate cancer, and differentiated thyroid carcinoma. Key theranostic radiopharmaceutical pairs, including Gallium-68-labeled DOTA-Tyr3-octreotate (Ga-68-DOTATATE) with Lutetium-177-labeled DOTA-Tyr3-octreotate (Lu-177-DOTATATE), and Gallium-68-labeled Prostate-Specific Membrane Antigen (Ga-68-PSMA) with Lutetium-177-labeled Prostate-Specific Membrane Antigen (Lu-177-PSMA), exemplify the "see-and-treat" principle central to this modality. This article further explores critical molecular targets such as somatostatin receptor subtype 2, prostate-specific membrane antigen, human epidermal growth factor receptor 2, CD20, and C-X-C chemokine receptor type 4, along with design principles for radiopharmaceuticals that optimize target specificity while minimizing off-target toxicity. Advances in imaging platforms, including positron emission tomography/computed tomography (PET/CT), single-photon emission computed tomography/CT (SPECT/CT), and hybrid positron emission tomography/magnetic resonance imaging (PET/MRI), have been instrumental in accurate dosimetry, therapeutic response assessment, and adaptive treatment planning. Integration of artificial intelligence (AI) and radiomics holds promise for enhanced image segmentation, predictive modeling, and individualized dosimetric planning. The review also addresses regulatory, manufacturing, and economic considerations, including guidelines from the United States Food and Drug Administration (USFDA) and European Medicines Agency (EMA), Good Manufacturing Practice (GMP) standards, and reimbursement frameworks, which collectively influence global adoption of theranostics. In summary, theranostics is poised to become a cornerstone of next-generation oncology, catalyzing a paradigm shift toward biologically driven, real-time personalized cancer care that seamlessly links diagnosis and therapy.

The integration of artificial intelligence (AI) into cardiovascular imaging and radiology offers the potential to enhance diagnostic accuracy, streamline workflows, and personalize patient care. However, the rapid adoption of AI has introduced complex ethical challenges, particularly concerning patient privacy, data handling, informed consent, and data ownership. This narrative review explores these issues by synthesizing literature from clinical, technical, and regulatory perspectives. We examine the tensions between data utility and data protection, the evolving role of transparency and explainable AI, and the disparities in ethical and legal frameworks across jurisdictions such as the European Union, the USA, and emerging players like China. We also highlight the vulnerabilities introduced by cloud computing, adversarial attacks, and the use of commercial datasets. Ethical frameworks and regulatory guidelines are compared, and proposed mitigation strategies such as federated learning, blockchain, and differential privacy are discussed. To ensure ethical implementation, we emphasize the need for shared accountability among clinicians, developers, healthcare institutions, and policymakers. Ultimately, the responsible development of AI in medical imaging must prioritize patient trust, fairness, and equity, underpinned by robust governance and transparent data stewardship.

To explore the perspectives of AI vendors on the integration of AI in medical imaging and oncology clinical practice. An online survey was created on Qualtrics, comprising 23 closed and 5 open-ended questions. This was administered through social media, personalised emails, and the channels of the European Society of Medical Imaging Informatics and Health AI Register, to all those working at a company developing or selling accredited AI solutions for medical imaging and oncology. Quantitative data were analysed using SPSS software, version 28.0. Qualitative data were summarised using content analysis on NVivo, version 14. In total, 83 valid responses were received, with participants having a global distribution and diverse roles and professional backgrounds (business/management/clinical practitioners/engineers/IT, etc). The respondents mentioned the top enablers (practitioner acceptance, business case of AI applications, explainability) and challenges (new regulations, practitioner acceptance, business case) of AI implementation. Co-production with end-users was confirmed as a key practice by most (52.9%). The respondents recognised infrastructure issues within clinical settings (64.1%), lack of clinician engagement (54.7%), and lack of financial resources (42.2%) as key challenges in meeting customer expectations. They called for appropriate reimbursement, robust IT support, clinician acceptance, rigorous regulation, and adequate user training to ensure the successful integration of AI into clinical practice. This study highlights that people, infrastructure, and funding are fundamentals of AI implementation. AI vendors wish to work closely with regulators, patients, clinical practitioners, and other key stakeholders, to ensure a smooth transition of AI into daily practice. Question AI vendors' perspectives on unmet needs, challenges, and opportunities for AI adoption in medical imaging are largely underrepresented in recent research. Findings Provision of consistent funding, optimised infrastructure, and user acceptance were highlighted by vendors as key enablers of AI implementation. Clinical relevance Vendors' input and collaboration with clinical practitioners are necessary to clinically implement AI. This study highlights real-world challenges that AI vendors face and opportunities they value during AI implementation. Keeping the dialogue channels open is key to these collaborations.

The application of artificial intelligence to enhance the clinical practice of ultrasound-guided regional anaesthesia is of increasing interest to clinicians, researchers and industry. The lack of standardised reporting for studies in this field hinders the comparability, reproducibility and integration of findings. We aimed to develop a consensus-based reporting guideline for research evaluating artificial intelligence applications for ultrasound scanning in regional anaesthesia. We followed methodology recommended by the EQUATOR Network for the development of reporting guidelines. Review of published literature and expert consultation generated a preliminary list of candidate reporting items. An international, multidisciplinary, modified Delphi process was then undertaken, involving experts from clinical practice, academia and industry. Two rounds of expert consultation were conducted, in which participants evaluated each item for inclusion in a final reporting guideline, followed by an online discussion. A total of 67 experts participated in the first Delphi round, 63 in the second round and 25 in the roundtable consensus meeting. The GRAITE-USRA reporting guideline comprises 40 items addressing key aspects of reporting in artificial intelligence research for ultrasound scanning in regional anaesthesia. Specific items include ultrasound acquisition protocols and operator expertise, which are not covered in existing artificial intelligence reporting guidelines. The GRAITE-USRA reporting guideline provides a minimum set of recommendations for artificial intelligence-related research for ultrasound scanning in regional anaesthesia. Its adoption will promote consistent reporting standards, enhance transparency, improve study reproducibility and ultimately support the effective integration of evidence into clinical practice.

Lung transplantation remains a critical treatment for end-stage lung diseases, yet it continues to have 1 of the lowest survival rates among solid organ transplants. Despite its life-saving potential, the field faces several challenges, including organ shortages, suboptimal donor matching, and post-transplant complications. The rapidly advancing field of artificial intelligence (AI) offers significant promise in addressing these challenges. Traditional statistical models, such as linear and logistic regression, have been used to predict post-transplant outcomes but struggle to adapt to new trends and evolving data. In contrast, machine learning algorithms can evolve with new data, offering dynamic and updated predictions. AI holds the potential to enhance lung transplantation at multiple stages. In the pre-transplant phase, AI can optimize waitlist management, refine donor selection, and improve donor-recipient matching, and enhance diagnostic imaging by harnessing vast datasets. Post-transplant, AI can help predict allograft rejection, improve immunosuppressive management, and better forecast long-term patient outcomes, including quality of life. However, the integration of AI in lung transplantation also presents challenges, including data privacy concerns, algorithmic bias, and the need for external clinical validation. This review explores the current state of AI in lung transplantation, summarizes key findings from recent studies, and discusses the potential benefits, challenges, and ethical considerations in this rapidly evolving field, highlighting future research directions.

Large language models (LLMs) are gaining attention for their potential to enhance radiology workflows by addressing challenges such as increasing workloads and staff shortages. However, limited knowledge among radiologists and concerns about their practical implementation and ethical implications present challenges. This study investigates radiologists' perspectives on the use of LLMs, exploring their potential benefits, challenges, and impact on workflows and professional roles. An exploratory, qualitative study was conducted using 12 semi-structured interviews with radiology experts. Data were analyzed to assess participants' awareness, attitudes, and perceived applications of LLMs in radiology. LLMs were identified as promising tools for reducing workloads by streamlining tasks like summarizing clinical histories and generating standardized reports, improving communication and efficiency. Participants expressed openness to LLM integration but noted concerns about their impact on human interaction, ethical standards, and liability. The role of radiologists is expected to evolve with LLM adoption, with a shift toward data stewardship and interprofessional collaboration. Barriers to implementation included limited awareness, regulatory constraints, and outdated infrastructure. The integration of LLMs is hindered by regulatory challenges, outdated infrastructure, and limited awareness among radiologists. Policymakers should establish clear, practical regulations to address liability and ethical concerns while ensuring compliance with privacy standards. Investments in modernizing clinical infrastructure and expanding training programs are critical to enable radiologists to effectively use these tools. By addressing these barriers, LLMs can enhance efficiency, reduce workloads, and improve patient care, while preserving the central role of radiologists in diagnostic and therapeutic processes.

Patients increasingly have direct access to their medical record. Radiology reports are complex and difficult for patients to understand and contextualize. One solution is to use large language models (LLMs) to translate reports into patient-accessible language. Objective This review summarizes the existing literature on using LLMs for the simplification of patient radiology reports. We also propose guidelines for best practices in future studies. A systematic review was performed following PRISMA guidelines. Studies published and indexed using PubMed, Scopus, and Google Scholar up to February 2025 were included. Inclusion criteria comprised of studies that used large language models for simplification of diagnostic or interventional radiology reports for patients and evaluated readability. Exclusion criteria included non-English manuscripts, abstracts, conference presentations, review articles, retracted articles, and studies that did not focus on report simplification. The Mixed Methods Appraisal tool (MMAT) 2018 was used for bias assessment. Given the diversity of results, studies were categorized based on reporting methods, and qualitative and quantitative findings were presented to summarize key insights. A total of 2126 citations were identified and 17 were included in the qualitative analysis. 71% of studies utilized a single LLM, while 29% of studies utilized multiple LLMs. The most prevalent LLMs included ChatGPT, Google Bard/Gemini, Bing Chat, Claude, and Microsoft Copilot. All studies that assessed quantitative readability metrics (n=12) reported improvements. Assessment of simplified reports via qualitative methods demonstrated varied results with physician vs non-physician raters. LLMs demonstrate the potential to enhance the accessibility of radiology reports for patients, but the literature is limited by heterogeneity of inputs, models, and evaluation metrics across existing studies. We propose a set of best practice guidelines to standardize future LLM research.

Cardiovascular disease remains a leading cause of morbidity and mortality worldwide, with conventional management often applying standardised approaches that struggle to address individual variability in increasingly complex patient populations. Computational models, both knowledge-driven and data-driven, have the potential to reshape cardiovascular medicine by offering innovative tools that integrate patient-specific information with physiological understanding or statistical inference to generate insights beyond conventional diagnostics. This review traces how computational modelling has evolved from theoretical research tools into clinical decision support systems that enable personalised cardiovascular care. We examine this evolution across three key domains: enhancing diagnostic accuracy through improved measurement techniques, deepening mechanistic insights into cardiovascular pathophysiology and enabling precision medicine through patient-specific simulations. The review covers the complementary strengths of data-driven approaches, which identify patterns in large clinical datasets, and knowledge-driven models, which simulate cardiovascular processes based on established biophysical principles. Applications range from artificial intelligence-guided measurements and model-informed diagnostics to digital twins that enable in silico testing of therapeutic interventions in the digital replicas of individual hearts. This review outlines the main types of cardiovascular modelling, highlighting their strengths, limitations and complementary potential through current clinical and research applications. We also discuss future directions, emphasising the need for interdisciplinary collaboration, pragmatic model design and integration of hybrid approaches. While progress is promising, challenges remain in validation, regulatory approval and clinical workflow integration. With continued development and thoughtful implementation, computational models hold the potential to enable more informed decision-making and advance truly personalised cardiovascular care.

ObjectiveTo study the implications of implementing artificial intelligence (AI) as a decision support tool in the Norwegian breast cancer screening program concerning cost-effectiveness and time savings for radiologists.MethodsIn a decision tree model using recent data from AI vendors and the Cancer Registry of Norway, and assuming equal effectiveness of radiologists plus AI compared to standard practice, we simulated costs, effects and radiologist person-years over the next 20 years under different scenarios: 1) Assuming a €1 additional running cost of AI instead of the €3 assumed in the base case, 2) varying the AI-score thresholds for single vs. double readings, 3) varying the consensus and recall rates, and 4) reductions in the interval cancer rate compared to standard practice.ResultsAI was unlikely to be cost-effective, even when only one radiologist was used alongside AI for all screening exams. This also applied when assuming a 10% reduction in the consensus and recall rates. However, there was a 30-50% reduction in the radiologists' screen-reading volume. Assuming an additional running cost of €1 for AI, the costs were comparable, with similar probabilities of cost-effectiveness for AI and standard practice. Assuming a 5% reduction in the interval cancer rate, AI proved to be cost-effective across all willingness-to-pay values.ConclusionsAI may be cost-effective if the interval cancer rate is reduced by 5% or more, or if its additional cost is €1 per screening exam. Despite a substantial reduction in screening volume, this remains modest relative to the total radiologist person-years available within breast centers, accounting for only 3-4% of person-years.

Technological innovations in robot-assisted ultrasound (RAUS) have remarkably advanced the development of precision and intelligent medical imaging diagnosis. This study aims to use bibliometric methods to systematically analyze the technological evolution and research frontiers in the RAUS field, providing valuable insights for future research. This study used the Web of Science Core Collection database to retrieve English-language research papers and reviews related to RAUS published between 2000 and 2024. Using analytical tools such as R (with the Bibliometrix package), VOSviewer, and CiteSpace, the study conducted a bibliometric analysis from multiple angles, including literature distribution, collaboration networks, and knowledge clustering. The visualization of analysis results comprehensively revealed the hot topics and emerging research frontiers within the RAUS field. The results reveal an exponential growth trend in RAUS research, with China leading in publication output (accounting for 28.51% of total publications), while the USA leads in terms of citation impact and international collaboration networks. Institutions such as Johns Hopkins University and Chinese Academy of Sciences emerge as highly productive core contributors. The research field has formed a multidimensional interdisciplinary landscape encompassing "mathematical sciences-engineering technology-medical health." The focus is on the integration of artificial intelligence (AI) and its clinical application translation. From 2000 to 2014, the development of "mobile robots" laid the cornerstone for further advancements. From 2015 to 2018, research focused on the development of "surgery" and "tumors" for medical applications. From 2019 to 2024, the core focus will be on "medical robots and systems," "artificial intelligence" and "robotic ultrasound," highlighting the transformation of technology into an AI-driven model. This study systematically reviewed the development of RAUS through bibliometric methods, enriching academic understanding of the field and providing valuable guidance for future technological iterations, clinical translation, and global cooperation to ultimately achieve precision medicine and balanced medical resources.